



MGC Diagnostics Corporation
through their subsidiaries Medical Graphics Corporation and Medisoft SA
350 Oak Grove Parkway
St. Paul, Minnesota USA, 55127-8599

FOR IMMEDIATE RELEASE

MGC DIAGNOSTICS CORPORATION ANNOUNCES NEWLY REPACKAGED ULTIMA SERIES™

SAINT PAUL, MN (May 13, 2015) —MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, announced today the release of its latest design of the Ultima Series™ cardiorespiratory diagnostic system, capable of performing both pulmonary function and metabolic testing in a single, modular, upgradeable platform, utilizing the latest technology. The system will be featured at the upcoming American Thoracic Society Meeting along with the full MGC Diagnostics Medical Graphics product line. Todd M. Austin, CEO of MGC Diagnostics, commented “This generation of MGC Diagnostic’s Ultima Series™, designed with both the patient and operator in mind, allows for maximum flexibility and operational efficiency, making it even easier to deliver cardiorespiratory diagnostic patient care with our intuitive, easy-to-use technology.”

For more information about MGC Diagnostic’s products, including the Ultima Series, please visit <http://mgcdiagnostics.com/products>.

About MGC Diagnostics

MGC Diagnostics Corporation (NasdaqCM: MGCD) is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and MediSoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company’s products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians’ offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance,



MGC DIAGNOSTICS®

MGC Diagnostics Corporation
through their subsidiaries Medical Graphics Corporation and Medisoft SA
350 Oak Grove Parkway
St. Paul, Minnesota USA, 55127-8599

business activities or plans that include the words “believes,” “expects,” “anticipates,” “intends” or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements,” in the Company’s Form 10-K for the year ended October 31, 2014, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contact: Wesley W. Winnekins
MGC Diagnostics Corporation
Chief Financial Officer
(651) 484-4874

Joe Dorame, Robert Blum, Joe Diaz
Lytham Partners, LLC
(602) 889-9700
mgcd@lythampartners.com